Homepage

Before he helped define criteria for the diagnosis of polycythemia vera (PV) and introduced interferon to treat it; before he chaired the guidelines committee for the treatment of chronic myeloid leukemia (CML) for the American Society of Hematology; and long before his name branded an internationally recognized clinic that specializes in myeloproliferative neoplasms (MPNs); Richard… Read More »Richard T. Silver, MD

Each day throughout September, MPNRF will post a fact about MPNs on social media. The growing list will appear HERE. The 30-day social media campaign will focus on: • The importance of clinical trials • What patients can learn about treatments currently in the clinical trial pipeline  • How to know if you qualify • How… Read More »Blood cancer Awareness month

The European Hematology Association’s EHA2022 Congress in Vienna brought together global research leaders, practitioners, and other participants in June to share the latest advances in hematology. Among those on MPNs were the following:   “ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFa axis mediated inflammation and fibrocyte generation in myeloproliferative neoplasms”   This study illustrated the crucial role… Read More »Advances of Note From EHA2022